NASDAQ:CRBP Corbus Pharmaceuticals Q4 2024 Earnings Results & Report $2.06 -0.37 (-15.23%) Closing price 04:00 PM EasternExtended Trading$2.05 -0.01 (-0.49%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Corbus Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 11, 2025. The company reported EPS of -$0.78 versus the -$1.02 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 11, 2025TimeBefore Market OpensConference Call8:30 AM ET Corbus Pharmaceuticals EPS ResultsActual EPS-$0.78Consensus EPS -$1.02Beat/MissBeat by +$0.24One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Corbus Pharmaceuticals Q4 2024 Earnings FAQ Did Corbus Pharmaceuticals beat earnings estimates for Q4 2024? Corbus Pharmaceuticals (NASDAQ:CRBP) reported earnings of -$0.78 per share for Q4 2024, beating the consensus estimate of -$1.02. The report was announced on Tuesday, March 11, 2025. Corbus Pharmaceuticals Earnings HeadlinesCSPC Receives $15 Mln Milestone Payment From Corbus For CRB-701 LicenseNovember 19 at 9:34 AM | rttnews.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Average Price Target of $35.67 According to BrokeragesNovember 19 at 4:14 AM | americanbankingnews.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 20 at 1:00 AM | Behind the Markets (Ad)Corbus Pharmaceuticals Reports Positive Oral Obesity Drug DataNovember 17 at 7:57 PM | theglobeandmail.comCorbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026November 16, 2026 | globenewswire.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Target Lowered at MizuhoNovember 13, 2026 | americanbankingnews.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines. Founded in 2014, Corbus previously focused on inflammatory and fibrotic diseases before shifting its research toward oncology and metabolic disorders. The company is led by co-founder and Chief Executive Officer Yuval Cohen.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.